Abstract Library

#1929 Safety and Efficacy of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial

Introduction: To date no systematic prospective trials have been carried out to evaluate safety and efficacy of unconventional doses of somatostatin analogs (SSAs) in neuroendocrine tumors (NETs). However,dose escalation of SSAs is a common strategy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Albertelli M, Campana D, Faggiano A, Spada F, Baldelli R,

Keywords: SSA high dose,

#1187 High-Dose Treatment with Somatostatin Analogs in Neuroendocrine Tumors

Introduction: Somatostatin analogs (SSA) effectively control symptoms in neuroendocrine tumours (NET), besides showing antiproliferative activity. In progressive or metastatic NET, increasing SSA dose or shortening the dosing interval are common clinical practice, though empirical.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Modica R

Authors: Modica R, Ramundo V, Marciello F, Marotta V, Pizza G,

Keywords: Somatostatin Analogs, Neuroendocrine Tumors,